Search research articles
Contact Us
Filters
Showing results (91-100 of 219) with videos related to
Page
of 22
Sort By:
Journal of the American Academy of Dermatology
|
October 8, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study
Kim A Papp, Shahram Jacobs, Howard Sofen, et al.
Dermatology and Therapy
|
December 23, 2022
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
Melinda Gooderham, Kim A Papp, Charles Lynde, et al.
Journal of Cutaneous Medicine and Surgery
|
May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I
David M Pariser, Kenneth B Gordon, Kim A Papp, et al.
The Journal of Investigative Dermatology
|
May 25, 2012
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial
Kim A Papp, Cathy Reid, Peter Foley, et al.
BMC Dermatology
|
October 8, 2016
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
Kim A Papp, Robert Bissonnette, Melinda Gooderham, et al.
Journal of the American Academy of Dermatology
|
April 19, 2017
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Jeffrey Crowley, Diamant Thaçi, Pascal Joly, et al.
Journal of the American Academy of Dermatology
|
March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial
Craig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
Dermatology and Therapy
|
July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
Kim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Blockchain in Healthcare Today
|
February 13, 2023
Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot
Baldwin C Mak, Bryan T Addeman, Jia Chen, et al.
Rheumatology and Therapy
|
August 5, 2022
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
Philip J Mease, Herbert Kellner, Akimichi Morita, et al.
Page
of 22
Search research articles
Search
Showing results (91-100 of 219) with videos related to
Sort By:
Page
of 22
Journal of the American Academy of Dermatology
|
October 8, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study
Kim A Papp, Shahram Jacobs, Howard Sofen, et al.
Dermatology and Therapy
|
December 23, 2022
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
Melinda Gooderham, Kim A Papp, Charles Lynde, et al.
Journal of Cutaneous Medicine and Surgery
|
May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I
David M Pariser, Kenneth B Gordon, Kim A Papp, et al.
The Journal of Investigative Dermatology
|
May 25, 2012
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial
Kim A Papp, Cathy Reid, Peter Foley, et al.
BMC Dermatology
|
October 8, 2016
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
Kim A Papp, Robert Bissonnette, Melinda Gooderham, et al.
Journal of the American Academy of Dermatology
|
April 19, 2017
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Jeffrey Crowley, Diamant Thaçi, Pascal Joly, et al.
Journal of the American Academy of Dermatology
|
March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial
Craig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
Dermatology and Therapy
|
July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
Kim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Blockchain in Healthcare Today
|
February 13, 2023
Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot
Baldwin C Mak, Bryan T Addeman, Jia Chen, et al.
Rheumatology and Therapy
|
August 5, 2022
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
Philip J Mease, Herbert Kellner, Akimichi Morita, et al.
Page
of 22